Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 3	2024-02-08		NCT05891093

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fudan University	653

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Nantong University	Nantong	China	6
Beijing Cancer Hospital	Beijing	China	208
Chongqing Cancer Hospital	Chongqing	China	16
Fudan University Shanghai Cancer Center	Shanghai	China	257
Fujian Medical University Union Hospital	Fuzhou	China	107
Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital	Guangzhou	China	1
Liaoning Cancer Hospital & Institute	Shenyang	China	10
Ningbo Medical Center Lihuili Hospital	Ningbo	China	15
Northern Jiangsu People's Hospital	Yangzhou	China	5
Shanghai First Maternity and Infant Hospital	Shanghai	China	4
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University	Shanghai	China	2
Sun Yat-sen University Cancer Center	Guangdong	China	2
The First Affiliated Hospital of Xi'an Jiaotong University	Xi’an	China	29
The First Hospital of China Medical University	Shenyang	China	12
West China Hospital of Sichuan University	Chengdu	China	117